Literature DB >> 24365172

Anti-D auto-immunization in a patient with weak D type 4.0.

M Ouchari1, T Chakroun1, S Abdelkefi1, H Romdhane1, B Houissa1, S Jemni Yacoub2.   

Abstract

We report the case of a 56-year-old patient with blood group O+C-c+E-e+K-, followed for a myelodysplasic syndrome and treated by regular pheno-identical and compatible (RBCs) transfusion since December 2007. In June 2009, a positive crossmatch was found with 2 RBCs O+C-c+E-e+K-. A positive anti-body screening with a positive autocontrol was detected and anti-D was unidentified in the patient's serum. The DAT was positive (IgG) and elution identified an anti-D. The following assumptions were then made: it could be a partial D phenotype with anti-D alloantibodies or RH: 1 phenotype with an anti-D auto-antibodies. Molecular analysis by multiplex PCR and sequencing have depisted a weak D type 4.0 phenotype. In October 2009, over three months of RH:-1 RBC transfusion, the antibody screening and DAT (IgG) remained positive, and an eluate made from the patient's erythrocytes contained an anti-D. All these funding confirmed the autoimmune nature of the anti-D. This case report illustrates the importance of a well-conducted and immunohematological laboratories test in order to distinguish between auto- or allo-immune of anti-D in a RH: 1 poly-transfused patients. This distinction is of great importance for transfusion support.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Auto anticorps; Genotypage RH; Génotypage RH; RAI; Test de Coombs; Transfusion

Mesh:

Substances:

Year:  2013        PMID: 24365172     DOI: 10.1016/j.tracli.2013.10.001

Source DB:  PubMed          Journal:  Transfus Clin Biol        ISSN: 1246-7820            Impact factor:   1.406


  7 in total

1.  Weak D in the Tunisian population.

Authors:  Mouna Ouchari; Houda Romdhane; Taher Chakroun; Saida Abdelkefi; Batoul Houissa; Slama Hmida; Saloua Jemni Yacoub
Journal:  Blood Transfus       Date:  2014-10-23       Impact factor: 3.443

2.  A proposal for a rational transfusion strategy in patients of European and North African descent with weak D type 4.0 and 4.1 phenotypes.

Authors:  Willy A Flegel; Thierry Peyrard; Jacques Chiaroni; Christophe Tournamille; Déborah Jamet; France Pirenne
Journal:  Blood Transfus       Date:  2018-05-03       Impact factor: 3.443

3.  Clinically relevant RHD-CE genotypes in patients with sickle cell disease and in African Brazilian donors.

Authors:  Ane C Gaspardi; Emília A Sippert; Mayra Dorigan De Macedo; Jordão Pellegrino; Fernando F Costa; Lilian Castilho
Journal:  Blood Transfus       Date:  2016-04-28       Impact factor: 3.443

4.  RHD and RHCE molecular analysis in weak D blood donors and in patients with Rh antibodies against their own corresponding Rh antigen.

Authors:  Thamy C Souza Silva; Bruno R Cruz; Sidneia S Costa; Akemi K Chiba; Melca M O Barros; Dante M Langhi; José O Bordin
Journal:  Blood Transfus       Date:  2020-07       Impact factor: 3.443

5.  It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work Group.

Authors:  S Gerald Sandler; Willy A Flegel; Connie M Westhoff; Gregory A Denomme; Meghan Delaney; Margaret A Keller; Susan T Johnson; Louis Katz; John T Queenan; Ralph R Vassallo; Clayton D Simon
Journal:  Transfusion       Date:  2014-12-01       Impact factor: 3.157

6.  Transfusion strategy for weak D Type 4.0 based on RHD alleles and RH haplotypes in Tunisia.

Authors:  Mouna Ouchari; Kshitij Srivastava; Houda Romdhane; Saloua Jemni Yacoub; Willy Albert Flegel
Journal:  Transfusion       Date:  2017-11-29       Impact factor: 3.157

7.  Variant RHD Types in Brazilians With Discrepancies in RhD Typing.

Authors:  Fernanda Carolina Alves Campos; Mariza Aparecida Mota; Maria Giselda Aravechia; Kelyan Bertani Torres; Carolina Bonet Bub; José Mauro Kutner; Lilian Castilho
Journal:  J Clin Lab Anal       Date:  2016-04-13       Impact factor: 2.352

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.